TY - JOUR
T1 - Elevation of erythrocyte zinc- and free protoporphyrins with metastatic spread in cancer patients
AU - Gorodetsky, Raphael
AU - Fuks, Zvi
AU - Peretz, Tamar
AU - Ginsburg, Hagai
PY - 1986/12
Y1 - 1986/12
N2 - A sensitive fluorometric method for the evaluation of erythrocyte levels of zinc-protoporphyrin (ZPP) and free-protoporphyrin (FPP) in diluted whole blood was used to survey patients with carcinomas in different stages of metastatic dissemination. ZPP levels in patients with primary tumor or with no evidence of metastatic disease were not different from those of normal donors. However, significantly higher ZPP levels were found in patients with carcinomas in correlation with evidence of metastatic disease, irrespective of the histological origin of the tumor. FPP levels were elevated in all stages of malignancy but were found 4 times higher than the normal levels in patients with metastatic malignancies. Similar increases in ZPP and FPP were detected in patients with inflammatory processes, suggesting a common effector of erythropoiesis in these pathological conditions and in metastatic diseases. Simultaneous detection of higher than normal ZPP and FPP levels in the blood of cancer patients may serve as an additional marker of metastatic dissemination in patients without clinical evidence of infectious or autoimmune diseases.
AB - A sensitive fluorometric method for the evaluation of erythrocyte levels of zinc-protoporphyrin (ZPP) and free-protoporphyrin (FPP) in diluted whole blood was used to survey patients with carcinomas in different stages of metastatic dissemination. ZPP levels in patients with primary tumor or with no evidence of metastatic disease were not different from those of normal donors. However, significantly higher ZPP levels were found in patients with carcinomas in correlation with evidence of metastatic disease, irrespective of the histological origin of the tumor. FPP levels were elevated in all stages of malignancy but were found 4 times higher than the normal levels in patients with metastatic malignancies. Similar increases in ZPP and FPP were detected in patients with inflammatory processes, suggesting a common effector of erythropoiesis in these pathological conditions and in metastatic diseases. Simultaneous detection of higher than normal ZPP and FPP levels in the blood of cancer patients may serve as an additional marker of metastatic dissemination in patients without clinical evidence of infectious or autoimmune diseases.
UR - http://www.scopus.com/inward/record.url?scp=0022862220&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(86)90089-1
DO - 10.1016/0277-5379(86)90089-1
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 3595676
AN - SCOPUS:0022862220
SN - 0277-5379
VL - 22
SP - 1515
EP - 1521
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
IS - 12
ER -
